The Human Cancer Models Initiative (HCMI) was created and funded by the US National Cancer Institute, Cancer Research UK, the foundation Hubrecht Organoid Technology, and the Wellcome Trust Sanger Institute. Together, these organizations develop policy and make programmatic decisions to contribute to the function of the HCMI.
The National Cancer Institute’s (NCI) Office of Cancer Genomics (OCG), within the Center for Cancer Genomics (CCG) manages the Cancer Model Development Centers (CMDCs). OCG also helps to facilitate communication between the CMDCs and the model development teams from Cancer Research UK (CRUK), the foundation Hubrecht Organoid Technology (HUB), and the Wellcome Trust Sanger Institute (WTSI).
CRUK and WTSI are co-funding organoid generation for the United Kingdom’s arm of the HCMI. CRUK have leveraged their unique network of clinical sites to access clinical samples and WTSI will derive and sequence organoid models.
The HUB is a not-for-profit organization founded by the Royal Netherlands Academy of Sciences and the University Medical Center Utrecht. The HUB will generate and sequence organoid models for the HCMI.
This group shares knowledge and protocols to advance and refine model development. Though the data collection mechanisms for each of these groups will not be identical, every effort will be made to maintain uniformity. The models will be made available through a single distributor, American Type Culture Collection.
The governance group of the funders has been established in order to ensure the coordination of all efforts within the HCMI.
ATCC is a non-profit biorepository whose mission within the HCMI will be to (1) acquire cancer models from the generating laboratories; (2) authenticate and preserve the models; and (3) globally distribute the models and standard operating procedures, imaging, and other model-specific information.